More articles from GU

You have access
Head to Head Comparison of 99mTc-HYNIC-PSMA-11 and Bone Scan in Metastatic Castration-Resistant Patients before Radioligand Therapy
Somaye Barashki, Kamran Aryana, Atena Aghaee, hamidreza ghorbani and Maryam Emadzadeh

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3080;
You have access
A Novel Automatic Bone Metastasis Delineation Method for Total-body PET/CT
Ruohua Chen, Fuxiao Shi, Shaowei Wang, Hongyan Sun, Yee Ling Ng, Haitao Zhao, Shuangliang Cao, Yun Zhou and Jianjun Liu

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3060;
You have access
Comparison of 68Ga-PSMA PET/CT and 68Ga-NT PET/CT in the detection of prostate cancer: results from a prospective single-center imaging trial
Wanqian Rao, Yongxiang Tang, Bei Chen, Shijun Xiang, Zehua Zhu, Ling Xiao, Haoyue Zhu and Shuo Hu

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3064;
You have access
Predictors of distant metastases at 68Ga-PSMA-11 PET/CT in early-recurrent hormone-sensitive prostate cancer (HSPC) patients
Guido Rovera, Serena Grimaldi, Sara Dall'Armellina, Roberto Passera, Marco Oderda, Giuseppe Iorio, Alessia Guarneri, Paolo Gontero, Umberto Ricardi and Desiree Deandreis

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3075;
You have access
PET-derived total tumor volume in the course of 225Ac-PSMA radioligand therapy in advanced mCRPC
Lena Unterrainer, Leonie Beyer, Mathias Zacherl, Andrei Todica, Sophie Carina Kunte, Annika Herlemann, Jozefina Casuscelli, Matthias Brendel, Nathalie Albert, Nina Schmidt-Hegemann, Wolfgang Kunz, Clemens Cyran, Franz Gildehaus, Christian Stief, Peter Bartenstein, Harun Ilhan and Marcus Unterrainer

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3061;
You have access
Early Lu-177 PSMA Radioligand Therapy in Metastatic Non-castrate or Castration-Sensitive Prostate Cancer: Long-Term Results
Harshad Kulkarni, Frankis Almaguel, Jingjing Zhang, Franz Robiller, Aviral Singh, Kevin Maupin, Anthony Chang, Richard P. Baum and Kenneth Pienta

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3083;
You have access
Semi-automatic Segmentation of Metastatic Tumor Load for 177Lu-PSMA Therapy
Subhadarshini Parhi, Song Xue, Andrei Gafita, Matthias Eiber, Axel Rominger, Ali Afshar-Oromieh and Kuangyu Shi

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3074;
You have access
Can primary PET/CT staging using [68Ga]Ga-RM2 and [18F]Choline predict recurrence in prostate cancer?
Reyhaneh Manafi-Farid, Ghasemali Divband, Ivan Jambor, Andre Mueller, Andrew Stephens, Heikki Minn and Mohsen Beheshti

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3072;
You have access
Initial outcome of phase I study of Lu-177 Ludotadipep treatment in metastatic castration-resistant prostate cancer patients
Joo Hyun O, Seunggyun Ha, Yeongjoo Lee, Sun Ha Boo, Hyong Woo Moon, Ie Ryung Yoo and Ji Youl Lee

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3088;
You have access
[68Ga]-PSMA-11 can clarify equivocal lesions on conventional imaging and change management decisions among men with previously treated prostate cancer
Avanti Gulhane, Daniel Lin, Atreya Dash, William Ellis, Yaw Nyame, George Schade, Jonathan Wright, Smith Apisarnthanarax, Jonathan Chen, Jay Liao, Wallner Kent, Emily Weg, Heather Cheng, Grivas Petros, Jessica Hawley, Andrew Hsieh, John Lee, Bruce Montgomery, Peter Nelson, Michael Schweizer, Todd Yezefski, Evan Yu and Delphine Chen

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3065;

Main menu

User menu

Search

More articles from GU

Pages